β-agonist-mediated relaxation of airway smooth muscle is protein kinase A-dependent

Sarah J. Morgan, Deepak A. Deshpande, Brian C. Tiegs, Anna M. Misior, Huandong Yan, Alena V. Hershfeld, Thomas C. Rich, Reynold A. Panettieri, Steven An, Raymond B. Penn

Research output: Contribution to journalArticle

Abstract

Inhaled β-agonists are effective at reversing bronchoconstriction in asthma, but the mechanism by which they exert this effect is unclear and controversial. PKA is the historically accepted effector, although this assumption is made on the basis of associative and not direct evidence. Recent studies have asserted that exchange protein activated by cAMP (Epac), not PKA, mediates the relaxation of airway smooth muscle (ASM) observed with β-agonist treatment. This study aims to clarify the role of PKA in the prorelaxant effects of β-agonists on ASM. Inhibition of PKA activity via expression of the PKI and RevAB peptides results in increased β-agonist-mediated cAMP release, abolishes the inhibitory effect of isoproterenol on histamine-induced intracellular calcium flux, and significantly attenuates histamine-stimulated MLC-20 phosphorylation. Analyses of ASM cell and tissue contraction demonstrate that PKA inhibition eliminates most, if not all, β-agonist-mediated relaxation of contracted smooth muscle. Conversely, Epac knockdown had no effect on the regulation of contraction or procontractile signaling by isoproterenol. These findings suggest that PKA, not Epac, is the predominant and physiologically relevant effector through which β-agonists exert their relaxant effects.

Original languageEnglish (US)
Pages (from-to)23065-23074
Number of pages10
JournalJournal of Biological Chemistry
Volume289
Issue number33
DOIs
StatePublished - Aug 15 2014

Fingerprint

Muscle Proteins
Cyclic AMP-Dependent Protein Kinases
Smooth Muscle
Muscle
Isoproterenol
Histamine
Proteins
Bronchoconstriction
Phosphorylation
Smooth Muscle Myocytes
Asthma
Calcium
Muscles
Peptides
Tissue
Fluxes

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Morgan, S. J., Deshpande, D. A., Tiegs, B. C., Misior, A. M., Yan, H., Hershfeld, A. V., ... Penn, R. B. (2014). β-agonist-mediated relaxation of airway smooth muscle is protein kinase A-dependent. Journal of Biological Chemistry, 289(33), 23065-23074. https://doi.org/10.1074/jbc.M114.557652

β-agonist-mediated relaxation of airway smooth muscle is protein kinase A-dependent. / Morgan, Sarah J.; Deshpande, Deepak A.; Tiegs, Brian C.; Misior, Anna M.; Yan, Huandong; Hershfeld, Alena V.; Rich, Thomas C.; Panettieri, Reynold A.; An, Steven; Penn, Raymond B.

In: Journal of Biological Chemistry, Vol. 289, No. 33, 15.08.2014, p. 23065-23074.

Research output: Contribution to journalArticle

Morgan, SJ, Deshpande, DA, Tiegs, BC, Misior, AM, Yan, H, Hershfeld, AV, Rich, TC, Panettieri, RA, An, S & Penn, RB 2014, 'β-agonist-mediated relaxation of airway smooth muscle is protein kinase A-dependent', Journal of Biological Chemistry, vol. 289, no. 33, pp. 23065-23074. https://doi.org/10.1074/jbc.M114.557652
Morgan SJ, Deshpande DA, Tiegs BC, Misior AM, Yan H, Hershfeld AV et al. β-agonist-mediated relaxation of airway smooth muscle is protein kinase A-dependent. Journal of Biological Chemistry. 2014 Aug 15;289(33):23065-23074. https://doi.org/10.1074/jbc.M114.557652
Morgan, Sarah J. ; Deshpande, Deepak A. ; Tiegs, Brian C. ; Misior, Anna M. ; Yan, Huandong ; Hershfeld, Alena V. ; Rich, Thomas C. ; Panettieri, Reynold A. ; An, Steven ; Penn, Raymond B. / β-agonist-mediated relaxation of airway smooth muscle is protein kinase A-dependent. In: Journal of Biological Chemistry. 2014 ; Vol. 289, No. 33. pp. 23065-23074.
@article{146a2246e9364a219a4e3f75b8ae5b9d,
title = "β-agonist-mediated relaxation of airway smooth muscle is protein kinase A-dependent",
abstract = "Inhaled β-agonists are effective at reversing bronchoconstriction in asthma, but the mechanism by which they exert this effect is unclear and controversial. PKA is the historically accepted effector, although this assumption is made on the basis of associative and not direct evidence. Recent studies have asserted that exchange protein activated by cAMP (Epac), not PKA, mediates the relaxation of airway smooth muscle (ASM) observed with β-agonist treatment. This study aims to clarify the role of PKA in the prorelaxant effects of β-agonists on ASM. Inhibition of PKA activity via expression of the PKI and RevAB peptides results in increased β-agonist-mediated cAMP release, abolishes the inhibitory effect of isoproterenol on histamine-induced intracellular calcium flux, and significantly attenuates histamine-stimulated MLC-20 phosphorylation. Analyses of ASM cell and tissue contraction demonstrate that PKA inhibition eliminates most, if not all, β-agonist-mediated relaxation of contracted smooth muscle. Conversely, Epac knockdown had no effect on the regulation of contraction or procontractile signaling by isoproterenol. These findings suggest that PKA, not Epac, is the predominant and physiologically relevant effector through which β-agonists exert their relaxant effects.",
author = "Morgan, {Sarah J.} and Deshpande, {Deepak A.} and Tiegs, {Brian C.} and Misior, {Anna M.} and Huandong Yan and Hershfeld, {Alena V.} and Rich, {Thomas C.} and Panettieri, {Reynold A.} and Steven An and Penn, {Raymond B.}",
year = "2014",
month = "8",
day = "15",
doi = "10.1074/jbc.M114.557652",
language = "English (US)",
volume = "289",
pages = "23065--23074",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "33",

}

TY - JOUR

T1 - β-agonist-mediated relaxation of airway smooth muscle is protein kinase A-dependent

AU - Morgan, Sarah J.

AU - Deshpande, Deepak A.

AU - Tiegs, Brian C.

AU - Misior, Anna M.

AU - Yan, Huandong

AU - Hershfeld, Alena V.

AU - Rich, Thomas C.

AU - Panettieri, Reynold A.

AU - An, Steven

AU - Penn, Raymond B.

PY - 2014/8/15

Y1 - 2014/8/15

N2 - Inhaled β-agonists are effective at reversing bronchoconstriction in asthma, but the mechanism by which they exert this effect is unclear and controversial. PKA is the historically accepted effector, although this assumption is made on the basis of associative and not direct evidence. Recent studies have asserted that exchange protein activated by cAMP (Epac), not PKA, mediates the relaxation of airway smooth muscle (ASM) observed with β-agonist treatment. This study aims to clarify the role of PKA in the prorelaxant effects of β-agonists on ASM. Inhibition of PKA activity via expression of the PKI and RevAB peptides results in increased β-agonist-mediated cAMP release, abolishes the inhibitory effect of isoproterenol on histamine-induced intracellular calcium flux, and significantly attenuates histamine-stimulated MLC-20 phosphorylation. Analyses of ASM cell and tissue contraction demonstrate that PKA inhibition eliminates most, if not all, β-agonist-mediated relaxation of contracted smooth muscle. Conversely, Epac knockdown had no effect on the regulation of contraction or procontractile signaling by isoproterenol. These findings suggest that PKA, not Epac, is the predominant and physiologically relevant effector through which β-agonists exert their relaxant effects.

AB - Inhaled β-agonists are effective at reversing bronchoconstriction in asthma, but the mechanism by which they exert this effect is unclear and controversial. PKA is the historically accepted effector, although this assumption is made on the basis of associative and not direct evidence. Recent studies have asserted that exchange protein activated by cAMP (Epac), not PKA, mediates the relaxation of airway smooth muscle (ASM) observed with β-agonist treatment. This study aims to clarify the role of PKA in the prorelaxant effects of β-agonists on ASM. Inhibition of PKA activity via expression of the PKI and RevAB peptides results in increased β-agonist-mediated cAMP release, abolishes the inhibitory effect of isoproterenol on histamine-induced intracellular calcium flux, and significantly attenuates histamine-stimulated MLC-20 phosphorylation. Analyses of ASM cell and tissue contraction demonstrate that PKA inhibition eliminates most, if not all, β-agonist-mediated relaxation of contracted smooth muscle. Conversely, Epac knockdown had no effect on the regulation of contraction or procontractile signaling by isoproterenol. These findings suggest that PKA, not Epac, is the predominant and physiologically relevant effector through which β-agonists exert their relaxant effects.

UR - http://www.scopus.com/inward/record.url?scp=84905987213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905987213&partnerID=8YFLogxK

U2 - 10.1074/jbc.M114.557652

DO - 10.1074/jbc.M114.557652

M3 - Article

VL - 289

SP - 23065

EP - 23074

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 33

ER -